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Abstract
Background: Hepatocyte nuclear factor 4a (HNF4a), a liver-specific transcription factor, plays a significant role in
liver-specific functions. However, its functions are poorly understood in the regulation of the inflammatory
response. In order to obtain a genomic view of HNF4a in this context, microarray analysis was used to probe the
expression profile of an inflammatory response induced by cytokine stimulation in a model of HNF4a knock-down
in HepG2 cells.
Results: The expression of over five thousand genes in HepG2 cells is significantly changed with the dramatic
reduction of HNF4a concentration compared to the cells with native levels of HNF4a. Over two thirds (71%) of
genes that exhibit differential expression in response to cytokine treatment also reveal differential expression in
response to HNF4a knock-down. In addition, we found that a number of HNF4a target genes may be indirectly
mediated by an ETS-domain transcription factor ELK1, a nuclear target of mitogen-activated protein kinase (MAPK).
Conclusion: The results indicate that HNF4a has an extensive impact on the regulation of a large number of the
liver-specific genes. HNF4a may play a role in regulating the cytokine-induced inflammatory response. This study
presents a novel function for HNF4a, acting not only as a global player in many cellular processes, but also as one
of the components of inflammatory response in the liver.
Background
Hepatocyte nuclear factor 4a (HNF4a)i sah i g h l yc o n -
served member of the nuclear receptor superfamily. It is
highly expressed in liver, kidney, intestine, and pancreas
in mammals. The active form of HNF4a is a homodi-
mer which recognizes a direct repeat (DR) of the
AGGTCA motif separated by 1 nucleotide (DR1) as a
binding site. HNF4a exerts direct transcriptional effects
on target genes, and it also works indirectly via the
positive regulation and negative regulation of other
liver-enriched transcription factors, each of which regu-
lates numerous downstream targets [1,2]. In contrast to
the liver-enriched transcription factors HNF1a,H N F 3 a,
HNF6, and CAAT/enhancer-binding protein (C/EBP)a,
which when disrupted in them o u s eg e n o m et h em i c e
are viable but show specific effects on hepatocyte differ-
entiation, metabolic function, and gene expression [3-6],
disruption of the mouse HNF4a gene is embryonic
lethal [7]. Studies with HNF4a deficient mice [8] have
established the critical role of this factor in regulating
diverse liver functions, including glucose, fatty acid and
cholesterol homeostasis, bile acid and urea biosynthesis
[9-11]. Defects in HNF4a function have been linked to
the human disease maturity onset diabetes of the young
1(MODY1) that results from haploinsufficiency of
HNF4a gene [12]. The pivotal role of HNF4a in the
maintenance of the differentiated hepatic phenotype is
highlighted by the exceptionally high number of poten-
tial target genes revealed by genome-scale target search
studies. Binding sites for HNF4a in genes expressed in
the liver occur more frequently than those of other
liver-enriched transcription factors [13], supporting the
idea that HNF4a is a global regulator of liver gene
expression.
Diverse signaling pathways regulate the transcription
of hepatocyte-specific genes. For example, trauma or
infection results in the release of proinflammatory cyto-
kines, e.g., interleukin (IL)-6, IL-1, and tumor necrosis
factor-a (TNF-a). The release of these cytokines has
long been known to stimulate the acute phase response
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plasma proteins known as acute phase proteins (APPs)
[14]. APPs are an established diagnostic tool as early
indicators of inflammation and disease. Many APPs play
beneficial roles in mediating the complex inflammatory
response and seeking to restore homeostasis, but pro-
longed exposure to acute phase conditions has been cor-
related with inflammatory syndromes such as sepsis and
multiple organ failure [15,16]. An understanding of the
molecular events that are involved in mediating the
response to external stresses can lead to the develop-
ment of therapeutic strategies for preventing the pro-
gression of the APR to the chronic inflammatory states,
while preserving its protective effects.
APP gene expression is regulated at the level of tran-
scription. Transcriptional activation is mediated by a
number of transcription factors. Beyond the well-known
nuclear factor-B, (NF-B) and signal transducer and
activator of transcription (STAT) family members,
HNF4a has been shown to be involved in the regulation
of liver-specific genes, including acute phase genes
[17,18]. It has been reported that in several injury mod-
els, injury leads to significant changes in binding activ-
ities of several liver-enriched transcription factors,
including HNF4a [18-20]. However, the functional ana-
lysis of HNF4a regulated-APR genes so far has mainly
relied on the description of the expression level of a few
selected genes [21]. To achieve a global view of HNF4a
during the APR, we used microarray analysis to evaluate
the expression profile in HepG2 cell, a human hepatoma
cell line. This cell line is similar to hepatocytes in terms
of biologic responsiveness [22-24] and is widely used as
a model system for studying the regulation of acute
phase protein synthesis in human liver [25-27]. In this
study, HepG2 cells were treated with either HNF4a
short hairpin RNA (shRNA) or cytokines (IL-6, IL-1b,
TNF-a) alone, or in combination of the two treatments.
Our results demonstrate that HNF4a is an important
regulator in liver gene expression. The highly significant
overlap of genes sensitive to HNF4a knock-down and
cytokine treatment suggests that HNF4a may be
involved in the regulation of the liver’s inflammatory
response. Our data also show that HNF4a may mediate
a certain amount of genes indirectly via the ETS-
domain transcription factor ELK1, a mitogen-activated
protein kinase (MAPK)-responsive transcription factor
[28,29], which is a previous undefined mechanism for
HNF4a regulation.
Results and discussion
Knock-down endogenous HNF4a in HepG2 cells
To study the role of HNF4a in liver-specific gene expres-
sion and the inflammatory response, the endogenous
HNF4a in HepG2 cells was knocked down by the
technique of RNA interference. As shown in Figure 1,
HNF4a shRNA caused a reduction in mRNA and protein
levels of HNF4a by more than 70% relative to control
levels assayed by real-time PCR and Western blot. Our
results indicate that HNF4a shRNA can efficiently and
specifically knock-down HNF4a in HepG2 cells [21].
HNF4a acts as a global regulator of liver-specific gene
expression
Given that HNF4a is a central mediator in hepatocyte-
specific gene expression and liver function, it is impor-
tant to identify the full spectrum of genes impacted by
the loss of HNF4a. To reach this end, microarray analy-
sis was performed to probe differences in gene expres-
sion between the control and HNF4a knock-down
HepG2 cells. Because we are particularly interested in
how HNF4a alters global gene expression patterns dur-
ing the inflammatory response, we also examined gene
expression in response to the inflammatory response
induced by cytokine treatment.
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Figure 1 Knock-down of HNF4a in HepG2 cells. HepG2 cells
were transfected with non-specific shRNA control or HNF4a shRNA
plasmid. mRNA and whole cell lysates were prepared for real-time
PCR (A) and Western blots (B), respectively. The results shown in (A)
represent the relative mRNA expression level normalized to GAPDH
mRNA level. The abundance of mRNA in the controls was set at 1.
Data represent mean ± SD of 4 replicates. An HNF4a antibody (sc-
6556, Santa Cruz Biotechnology) and b-actin (Sigma) antibody, used
as an internal loading control, were utilized for Western blot (B).
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Page 2 of 14A two-way ANOVA was performed to identify differ-
entially expressed genes and classify the observed
expression patterns. This procedure identifies genes
with altered expression in response to HNF4a shRNA
or cytokines alone, or in combination HNF4a knock-
down with cytokine treatments. The entire dataset is
available at the NCBI Gene Expression Omnibus http://
www.ncbi.nlm.nih.gov/geo/ with the accession number
GSE15991. From this analysis, a total of 14,220 unique
probesets were found to be present in the samples.
Two-way ANOVA analysis was then used to determine
which probesets were differentially expressed between
the untreated control and treated groups. The ANOVA
analysis identified four categories of interest (Figure 2):
Category A, “HNF4a shRNA only” contains genes that
are significantly regulated by HNF4a shRNA, but not by
cytokines; Category B, “Cytokine only” contains genes
that respond to cytokine treatment, but not to HNF4a
knock-down; Category C, “Additive” contains genes
whose expression is dependent on both treatments with
cytokines and HNF4a shRNA, and the effect of both
treatments is additive, suggesting that the two treat-
ments likely influence expression independent of each
other. Finally, Category D, “Interactive” contains genes
that exhibit an expression pattern dependent on both
treatments in which the effect of the two treatments is
not additive, rather interactive between each other. The
genes with significantly altered expression and fold
changes in each category are listed in Additional file 1.
Utilizing K-means clustering, the genes in the category
A and category B (Figure 2A and 2B) were clustered
into 2 clusters for each category; Category C and cate-
gory D (Figure 2C and 2D) were clustered into 4 and 8
clusters, respectively.
As shown in Table 1, we identified a total of 5,173 pro-
besets (36% of the 14,220 probesets on the Affymetrix HG
U133A 2.0 GeneChip with sequence-specific signal in our
experiment) that exhibited differential expression in
response to HNF4a knock-down (false discovery rate,
FDR< 0.01). Of these, 3,606 probesets were only affected
by HNF4a knock-down, and were not differentially
expressed in response to cytokine stimulation (Category
A). The remaining 1,567 probesets exhibited a differential
expression pattern that was either specific to the combined
effect of HNF4a knock-down and cytokine treatments
(502 probesets; Category D) or the genes that were
affected by HNF4a knock-down and cytokine treatments
independently (1,065 probesets; Category C). Among the
probesets affected by HNF4a knock-down independently
(Category A and Category C), many (3,088 of 4671 probe-
sets) were up-regulated when HNF4a expression was
reduced. These observations may suggest that HNF4a
directly or indirectly regulates a large number of liver-spe-
cific gene expressions. We found that in our experimental
conditions more genes appeared to be down-regulated or
repressed under a normal level of HNF4a in HepG2 cells.
This finding is not in agreement with the description that
HNF4a functions primarily as a transcription activator
[8,30], but is more in line with the observation that
HNF4a can act as a suppressor of transcription [31,32].
To exclude an off-target effect of knock-down in our
study, siRNA rescue experiments were performed. A res-
cue effect was observed in the knock-down HNF4a
HepG2 cells transfected with an HNF4a siRNA-resistant
construct generated by introducing silent substitutions in
the HNF4a siRNA-target region (Additional files 2 and 3).
These siRNA rescue experiments suggest that the HNF4a
shRNA used in this study can specifically knock-down
HNF4a in HepG2 cells.
The observation that a large number of liver specific
genes are affected by HNF4a is consistent with the
recent work of Odom et al. [13], in which the authors
demonstrated that HNF4a binds the promoters of 12%
of genes in human liver cells, whereas HNF1a binds the
promoters of only 1.6% of genes using chromatin immu-
noprecipitation-chip (ChIP-chip). In order to determine
what fraction of genes that showed differential expres-
sion in response to HNF4a knock-down is likely to be
bound by HNF4a, we compared our microarray expres-
sion data to the ChIP-chip data reported by Odom et al.
Only those genes in the Odom’sd a t af o rw h i c ht h e r e
were probesets on our microarray were considered. We
found that 54% (659 of 1,219) of the genes bound by
HNF4a detected by ChIP-chip also showed differential
expression in response to HNF4a knock-down on our
microarray. A Fisher-Exact test was used to test whether
the fraction of genes in the Odom et al. data that are
differentially expressed in response to HNF4a knock-
down is significantly greater than the fraction of genes
probed on our microarray that exhibit HNF4a-depen-
dent expression, resulting in a highly significant p-value
of p =2 . 9×1 0
-33. A similar analysis determined that
13% (659/5,173, p =2 . 8×1 0
-17) of those genes that
exhibit differential expression in response to HNF4a
knock-down were reported by Odom et al. to be bound
by HNF4a. These results suggest that a substantial frac-
tion of HNF4a-sensitive genes may be indirect targets
of HNF4a. However, the differences seen might also be
caused by the significant differences in the experimental
methods used such as the data from ChIP-chip were
derived from human hepatocytes, while our experiment
was performed on HepG2 cells.
Majority of genes affected by cytokines are also affected
by HNF4a knock-down
As shown in Table 2, we found that expression of 15%
of the probesets (2,202 of 14,220) was affected by treat-
ment with cytokine alone (635 probesets; Category B),
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Figure 2 The clustering expression profiles of up- and down-regulated genes. A global transcriptional view of HepG2 cells in response to
the treatment with cytokines and HNF4a knock-down alone (2 and 3) or in combination (4) is shown. Each group has 4 replicates. Relative
expression values are expressed as a color code (bar color chart on the bottom, red up- and blue down-regulation). (A), Category A contains
genes that are significantly regulated by HNF4a knock-down, but not by cytokines; (B), Category B contains genes that respond to cytokine
treatment, but not to HNF4a knock-down; (C), Category C contains genes whose expression is dependent on both treatments with cytokines
and HNF4a knock-down in an independent manner; (D), Category D has genes that exhibit an expression pattern dependent on both
treatments in an interactive manner.
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Page 4 of 14and treatment with both HNF4a shRNA and cytokines
(1567 probesets; Category C and D). Of the probesets
that are differentially expressed in response to cytokine
treatment but non-interactively with HNF4a knock-
down (Category B and C) almost twice as many are
down-regulated (1,144 probesets) as up-regulated (556
probesets). This may reflect that during the APR, there
is an important role for the down-regulation of specific
genes in response to an inflammatory stimulation,
although the up-regulation of APR genes has been more
extensively studied than those that are down-regulated.
More interestingly, we found that majority of those
genes that exhibit differential expressions in response to
cytokine treatment also reveal differential expression in
response to HNF4a knock-down. Of the 2,202 probesets
f o u n dt ob er e s p o n s i v et oc y t o k i n et r e a t m e n t ,1 , 5 6 7
(71%) of them also show altered expression in response
to knock-down of HNF4a, while only 635 probesets are
not influenced by HNF4a knock-down (Table 2). The
p-value for this level of over-representation, calculated
using a Fisher Exact test, is 1.8 × 10
-207.S o m eo ft h e s e
probesets are altered independently by cytokine treat-
ment and reduction in HNF4a levels (1,065 probesets;
Category C), while others show a pattern of expression
where the effect of cytokine treatment and reduction in
HNF4a levels is interdependent (502 probesets; Cate-
gory D). When more stringent criteria were used for fil-
tering our data, and only those probesets in response to
cytokine treatment and/or HNF4a knock-down that
change expression by more than two fold were chosen,
we found that an even greater percentage (519/597, 87%)
of probesets regulated by cytokines are also regulated by
HNF4a (Table 2). This over-representation suggests that
HNF4a m a yp l a yas i g n i f i c a n tr o l ei no r c h e s t r a t i n gt h e
inflammatory response in hepatic gene expression.
Although there is significant overlap between those
probesets regulated by cytokines and those regulated by
HNF4a knock-down (Category C and D), the expression
patterns in response to these two treatments are varied.
For some probesets the response to HNF4a knock-
down are in the same direction as cytokine treatment
(99 probesets, clusters 4 and 7 in the interactive cate-
gory D, Figure 2D). This group of genes may represent
a direct linkage of HNF4a with the injury response and
will serve as interesting targets for further study of the
complex role of HNF4a in the response to injury. For
other genes the effect of each treatment is in opposition
to each other (144 probesets, clusters 3 and 5 in Cate-
gory D, Figure 2D). These diverse regulatory patterns
observed suggest that the effects of HNF4a knock-down
as that of cytokine treatment are pleiotropic in nature
affecting transcription events at basic levels allowing
individual gene responses to be highly variable but none
the less altered.
Previous work by our lab has demonstrated that
HNF4a binding activities are significantly reduced in a
burn injury mouse model and a cytokine-induced APR
cell culture model [18,21]. We have shown, utilizing the
cell culture model, that the decrease in HNF4a binding
activity also affects HNF4a’s ability to transactivate tar-
get genes [21]. The injury induced decrease in HNF4a
binding may affect cellular transcription by simply
decreasing the amount of effective HNF4a available for
binding. Our ability to efficiently decrease HNF4a con-
centration utilizing RNA interference technique may
mimic this decrease in HNF4a binding ability isolating
this aspect of HNF4a’s role in the injury response.
Genes annotated as participating in inflammatory
response exhibit distinct expression patterns
In order to further explore the function of HNF4a in
the inflammatory response, a set of 170 genes annotated
as playing a key role in inflammatory response was
obtained from Gene ontology (GO) http://geneontology.
org. These inflammatory response genes are highly
enriched in the set of probesets up-regulated by cyto-
kines (p =3 . 5×1 0
-3, 334% above background), but not
in those probesets down-regulated after cytokine treat-
ment. Slightly more inflammatory response genes are
up-regulated in response to HNF4a knock-down than
those that are down-regulated, but the difference is not
statistically significant (p > 0.05).
Table 1 Genes exhibiting altered expression by the
treatment with HNF4a shRNA alone and in combination
with cytokines
Cut-off
1 HNF4 shRNA only
2 HNF4 shRNA+Cytokines
3 Total
Additive Interactive Total
FDR < 0.01 3606 1065 502 1567 5173
2-fold 878 223 296 519 1397
Two methods of cut-off
1, FDR (false discovery rate) and 2-fold changes
compared to untreated controls, are shown. HNF4 shRNA only
2 (Category A)
denotes that gene expressions are significantly changed by HNF4a shRNA,
but not by cytokines. HNF4 shRNA+Cytokines
3 indicate that gene expressions
are significantly changed by both HNF4a shRNA and cytokines, including the
additive (Category C) and interactive (Category D) effects.
Table 2 Genes exhibiting altered expression by the
treatment with cytokines alone and in combination with
HNF4a shRNA
Cut-off Cytokine only
1 HNF4 shRNA+Cytokines
2 Total
Additive Interactive Total
FDR < 0.01 635 1065 502 1567 2202
2-fold 78 223 296 519 597
Cytokine only
1 (Category B) indicates that gene expressions are significantly
changed by cytokines, but not by HNF4a shRNA. HNF4 shRNA+Cytokines
2
indicate that gene expressions are significantly changed by both HNF4a
shRNA and cytokines, including the additive (Category C) and interactive
(Category D) effects.
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Page 5 of 14To determine whether certain expression patterns are
associated with functional annotations, we further tested
each cluster in each category using ANOVA analysis.
While HNF4a-regulated probesets as a whole are not
significantly enriched for the annotated inflammatory
response genes, two expression clusters in the interac-
tive category D are highly enriched for these genes. Of
the 5,173 probesets regulated by HNF4a knock-down,
25 of them are annotated as participating in inflamma-
tory response, and 14 of these genes fall into one of two
clusters. One of these clusters (cluster 8, Category D)
contains 101 probesets that are dramatically up-regu-
lated by the combination of HNF4a shRNA and cyto-
kine treatment, but exhibit relatively low levels of
expression in the untreated controls, and the cells trea-
ted by either HNF4a knock-down or cytokines alone.
Nine of 101 probesets in cluster 8 are annotated in GO
as participating in the inflammatory response, which is
8.2 times more than expected by chance (p = 2.2 × 10
-6)
(Figure 3A). Another cluster (cluster 1, Category D)
contains 41 probesets expressed in moderate levels
under all conditions except HNF4a shRNA treatment in
the absence of cytokines, in which they are markedly
down-regulated. In this cluster, five genes are annotated
as inflammatory response genes which is over 11.3
times more than expected by chance (p =8 . 8×1 0
-5)
(Figure 3B). While it is not immediately clear why genes
that play a role in inflammatory response are enriched
in these particular expression clusters, it is intriguing
that such genes exhibit similar HNF4a-dependent
expression. These inflammatory response genes in clus-
ter 8 and cluster 1 present good candidates for further
study.
To confirm the microarray results, we chose several
transcripts from category D, cluster 8 (C5 and LBP) and
cluster 1 (SERPINA 3 and C4A), and measured their
expressions with real-time PCR using the same RNA
samples used for microarray studies. All of them showed
a high concordance between microarray and real-time
PCR data. Figure 4 illustrates the comparison of the
expression levels between microarray (Figure 4A) and
real-time PCR (Figure 4B) for the selected transcripts
from cluster 8 and cluster 1 (Category D).
In addition to testing for enrichment of inflammatory
response genes, enrichment for broad categories of func-
tionality was calculated for each cluster. GO terms of all
26 top level biological processes were analyzed. We
found that GO term of metabolism is significantly
enriched in genes exhibiting HNF4a-dependent expres-
sion (Figure 5). As previous work [9,30,33] has noted
that HNF4a plays a significant role in regulating meta-
bolism in the liver, it is not surprising that the GO term
for metabolism is HNF4a-dependent. Thirty percent of
genes (1,530 of 5,173) that are differentially expressed in
response to HNF4a knock-down are annotated as parti-
cipating in a metabolic process, resulting in a Fisher
Exact p-value of 2.6 × 10
-18.
HNF4a may regulate a large number of targets via the
ETS family of transcription factors
To gain insight into the complex transcriptional net-
works that regulate hepatic gene expression, the promo-
ter region (-1 kb to +0.5 kb relative to the transcription
start site, TSS) of genes was extracted, and potential
transcription factor binding sites were identified using
Clover [34]. By extensive search of the genes found to
be differentially expressed as a function of HNF4a
knock-down, we found that the HNF4a motif is not sta-
tistically enriched in the promoters of genes whose
expression changes in response to HNF4a knock-down
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Figure 3 Inflammatory response genes are enriched in two
clusters within the interactive category (Category D). Expression
profiles of up- and down-regulated genes in the different groups
treated by cytokines and HNF4a knock-down alone (2 and 3) or in
combination (4) are shown. Each group has 4 replicates. Relative
expression values are expressed as a color code (bar color chart on
the bottom, red up- and blue down-regulation). Inflammatory
response genes (listed at the right side of the graph) extracted from
GO are highly enriched in two different clusters (A and B). Gene
abbreviations: VNN1, vanin 1; SAA1/SAA2, serum amyloid A1/serum
amyloid A2; C5; complement component 5; CX3CL1, chemokine (C-
X3-C motif) ligand 1; LBP, lipopolysaccharide binding protein; PTX3,
pentraxin-related gene, rapidly induced by IL-1 beta; PTAFR, platelet-
activating factor receptor; NMI, N-myc (and STAT) interactor; ORM1/
ORM2, orosomucoid 1/orosomucoid 2; C4A/C4B, complement
component 4A/complement component 4B; CEBPB, CCAAT/
enhancer binding protein (C/EBP), beta; SERPINA3, serpin peptidase
inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3;
CCL20, chemokine (C-C motif) ligand 20; HIF1A, hypoxia-inducible
factor 1, alpha subunit (basic helix-loop-helix transcription factor).
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Page 6 of 14relative to promoters chosen randomly from throughout
t h eg e n o m e( p > 0.05). There are several possible rea-
sons for this observation. Firstly, HNF4a binding sites
may be located far up-stream or down-stream of the
TSS, although the results still remain the same when we
extended our search up to 5 kb up-stream and 2.5 kb
down-stream of the TSS. Secondly, there might be a
fraction of sites that bind HNF4a b u td i f f e rf r o mt h e
established consensus. Thirdly, HNF4a may interact
with proximal promoters through formation of enhan-
cer/promoter loops with HNF4a binding to distal regu-
latory element [35]. Yet another possibility is that
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
0
5
10
15
20
25
30
35
40
45
50
0
500
1000
1500
2000
2500
3000
3500
4000
4500
0.0
0.5
1.0
1.5
2.0
2.5
0
1
2
3
4
5
6
7
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
0.0
0.5
1.0
1.5
2.0
2.5
A. B.
Ctr Cyto shRNA shRNA
 +Cyto
Ctr Cyto shRNA shRNA
 +Cyto
Ctr Cyto shRNA shRNA
 +Cyto
Ctr Cyto shRNA shRNA
 +Cyto
Ctr Cyto shRNA shRNA
 +Cyto
Ctr Cyto shRNA shRNA
 +Cyto
Ctr Cyto shRNA shRNA
 +Cyto
Ctr Cyto shRNA shRNA
 +Cyto




















 



















 










Microarray Real-time PCR
N
o
r
m
a
l
i
z
e
d
 
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
C5 C5
LBP LBP
SERPINA3 SERPINA3
C4A/C4B C4A
Figure 4 Confirmation of microarray results using quantitative real-time PCR.( A), Raw intensity values were measured using microarray.
(B), Real-time PCR results for the same genes are expressed as the relative mRNA expression level normalized by GAPDH mRNA level. The
abundance of mRNA in the controls was set at 1. Data represent mean ± SD of 4 replicates. Ctr, Control; Cyto, Cytokines; shRNA, HNF4a shRNA;
shRNA+Cyto, HNF4a shRNA plus Cytokines. *p < 0.05 and **p < 0.01 indicate a significant difference compared to control. Gene abbreviations
are the same as described in Figure 3 legend.
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Page 7 of 14HNF4a might act as a cofactor, interacting with other
transcription factors and not directly bind to DNA.
Indeed, we found that the binding sites for the ETS
family of transcription factors including ELK1, ELK4 and
GA binding protein transcription factor A (GABPA) are
highly enriched in the HNF4a knock-down group. The
binding motifs for ELK1 (p =4 . 0×1 0
-7), ELK4 (p =1 . 1 4×
10
-10) and GABPA (p =3 . 4×1 0
-5) are very similar (Figure
6), and all significantly enriched in the promoter regions
of genes affected by HNF4a knock-down. This mirrors a
finding by Smith et al. [36], where they showed that ELK1
binding motifs are enriched in the promoters of genes also
bound by HNF4a. Moreover, in this study we found that
ELK1 and ELK4 genes exhibit significant differential
expression in response to HNF4a knock-down. ELK1 is
up-regulated when HNF4a is knocked down, while ELK4
is down-regulated. These results suggest that HNF4a may
regulate a substantial number of genes via ELK transcrip-
tion factors.
The transcription factor ELK1 is of particular interest
as this protein is a nuclear target of extracellular-regu-
lated kinases (ERKs) and plays a pivotal role in immedi-
ate early gene induction by external stimuli [28,29]. It
has been known that HNF4a expression is modulated
by MAP kinase signaling [37,38]. Li et al. [39] reported
that ELK1 is involved in the inflammatory response via
stimulation of chemokine by thrombin. These observa-
tions suggest that the relationship between ELK1 and
HNF4a may be especially relevant to understanding the
role of HNF4a in regulating the inflammatory response.
By searching for ELK1 binding site in the HNF4a
regulated genes (5173 genes), we identified 373 genes
multi-cellular-organism-process
locomotion
cell-killing
rhythmic-process
multiple-organism-process
biological-adhesion
reproductive-process
immune-system-process
reproduction
developmental-process
response-to-stimulus
viral-reproduction
pigmentation
regulation-biological-process
biological-regulation
growth
positive-regulation-of-biological-process
death
localization
establishment-of-localization
negative-regulation-of-biological-process
anatomical-structure-formation
cellular-component-biogenesis
cellular-component-organization
cellular-process
metabolic-process
1
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1
0
5
0
-log (p-value)
Figure 5 Gene ontology analysis. Twenty six broad categories of biological processes were analyzed for genes that exhibit HNF4a-dependent
expression. Significance levels are plotted as-log (p value). One-tail p-values were calculated using the Fisher Exact test. Threshold (line) denotes
the p = 0.002 level, which is the threshold for significance after Bonferroni correction.
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Page 8 of 14that have one or more potential ELK1 binding sites in
their promoter regions (-1 kb to +0.5 kb) (Additional
file 4). To define a functional link between HNF4a and
ELK1, we selected 4 genes (COL4A1, ZNF175, MMP15
and SEC24A). These genes all were found having an
ELK1 binding motif (CCGGAAG/A, Figure 6), but no
HNF4a binding motif in their proximal promoter
regions, and from our microarray analysis their expres-
sions were shown to be either up-regulated (COL4A1,
ZNF175) or down-regulated (MMP15 and SEC24A) by
HNF4a knock-down. The expression of these potential
ELK1 target genes was examined by real-time PCR in
HepG2 cells treated with siRNA to knock-down HNF4a
and/or ELK1 alone or both together. As shown in Figure
7, the expression of ELK1 can be efficiently knocked-
down by siRNA. The knock-down of HNF4a resulted in
a significantly greater ELK1 expression compared to
control (p < 0.05), and the ELK1 expression was not sig-
nificantly affected by cytokine treatment, which are con-
sistent with our microarray data. We propose that
HNF4a may indirectly regulate a number of genes
through ELK1 transcription factor based on the observa-
tion that the ELK1 binding site is highly enriched in
genes affected by HNF4a knock-down. It was predicted
that if a higher ELK1 expression induced by HNF4a
knock-down affects the transcriptional outcomes of
ELK1-target genes, we should see an opposite regulatory
effect on these gene transcriptions when the ELK1 level
is reduced. The results (Figure 8) show that when the
cells were treated with siELK1 either alone or with
siHNF4a, the two genes up-regulated by HNF4a knock-
down (Figures 8A and 8B) are expressed at significantly
lower levels compared to HNF4a knocked-down (p <
0.01). In contrast, the genes down-regulated by HNF4a
knock-down (Figures 8C and 8D) show significantly
increased expression compared to siHNF4a (p < 0.01).
This result is consistent with a direct effect of ELK1
level induced by the decrease of HNF4a concentration
on a subset of ELK1-target genes. However, these find-
ings could be explained by another mechanism by
which an HNF4a/ELK1 complex is formed, leading to
alterations in the regulation of a group of genes. To test
this hypothesis, chromatin immunoprecipitation (ChIP)
assays were performed. An HNF4a antibody was used
to immunoprecipitate chromatin from HepG2 cells.
Specific PCR primers were utilized to amplify a DNA
fragment with an ELK1 binding motif, and without an
HNF4a binding motif. As shown in Figure 9, HNF4a
was able to interact with these genes containing ELK1
binding sites, and the interactive ability of HNF4a was
significantly reduced after the knock-down of ELK1.
Interestingly, when the HNF4a binding motif was
further searched using a web-based search tool, HNF4
Motif Finder [40], a potential HNF4 binding site was
identified in the promoter region of MMP15, which
could lead to a direct binding of HNF4a when HNF4a
antibody was used to immunoprecipitate chromatin.
However, if HNF4a binding to MMP15 is independent
of ELK1, when ELK1 is knocked down, one would
expect to see no change in the binding of MMP15 in
the ChIP assay, this is not the case as shown in Figure
9. Furthermore, we found that ELK1 can directly bind
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axis indicates amount of information at each position in the motif.
These logos were generated from information obtained from the
JASPAR core database [42]. (A), ELK1 binding motif; (B), ELK4
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Page 9 of 14to its potential ELK1 binding site in MMP15 utilizing
electrophoretic mobility shift analysis (data not shown).
Given these findings, we hypothesize that HNF4a may
indirectly mediate gene expression, in part, through a
co-operative interaction with ELK1, and possibly also
with other ETS transcription factors. Others have
reported that a number of ETS family proteins interact
and crosstalk with several transcription factors including
AP-1, NF-B and Stat-5 to co-regulate the expression of
cell-type specific genes. Such interactions coordinate
cellular processes in response to diverse signals includ-
ing cytokines, growth factors, antigen and cellular stres-
ses [41], here we believe that we have uncovered a novel
interplay between the transcription factors HNF4a and
ELK1 for controlling gene expression in the liver.
Conclusions
HNF4a is a major regulator of hepatic gene expression.
The complex physiological effects of HNF4a on the reg-
ulation and maintenance of hepatic phenotype are likely
involved both directly and indirectly in a systemic
response such as that seen in a response to injury or
inflammation. Our microarray data are consistent with a
broad effect of HNF4a on liver functions, and more
importantly, the microarray analysis provides a genomic
view for the role of HNF4a in the inflammation
response, which greatly extends the observations from
both animal- and cell culture-injury models. However,
more experimentation and a focus on individual
pathways will need to be done before a full picture of
HNF-4a’s role in the modulation of hepatic phenotype
by injury can be obtained.
Methods
Cell culture and treatments
HepG2 cells (ATCC # HB-8065), human hepatoma cells,
were grown in Dulbecco Modified Eagle Medium
(DMEM) supplemented with penicillin (100 units/ml),
streptomycin (100 μg/ml), and 10% heat-inactivated fetal
b o v i n es e r u m( M e d i a t e c h ,H e r n d o n ,V A )a t3 7 ° Ci na
humidified atmosphere with 5% CO2.
The inflammatory response in HepG2 cells was stimu-
lated with a cytokine mixture consisting of 1 ng/ml of
recombinant human IL-1b, 10 ng/ml of IL-6, and 10 ng/
ml of TNF-a (PeproTech, Rocky Hill, NJ) in serum-free
medium for 18 h.
Knock-down of HNF4a in HepG2 cells was carried
out as described previously [21]. Briefly, shRNA plas-
mids (HNF4a shRNA and non-specific control shRNA)
were transfected into HepG2 cells with the Nucleofector
(Amaxa Biosystem, Cologne, Germany) T-28 protocol
following the manufacturer’s instructions. Knock-down
of ELK1 in HepG2 cells was performed by transfection
with small interfering RNA (siRNA) (Ambion, Austin,
TX) using lipofectamine 2000 reagent (Invitrogen, Carls-
bad, CA) according to the manufacturer’si n s t r u c t i o n s .
Twenty-four hours after transfection, the cells were
placed in serum-free medium for 5 h and then either
treated or untreated with cytokines for 18 h.
The different treated HepG2 cells were divided into four
groups: Group 1, control: the cells were transfected with
non-specific control shRNA; Group 2, HNF4a shRNA: the
cells were transfected with HNF4a shRNA; Group 3, cyto-
kines: the control cells were transfected with non-specific
control shRNA and then treated with cytokines; Group 4,
HNF4a shRNA with cytokine treatment: the cells were
transfected with HNF4a shRNA prior to the treatment with
cytokines. Four biological replicates from separate experi-
ments were performed for each of the four study groups.
Total RNA isolation and real-time PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s
instructions. Quantitative real-time PCR analysis was
conducted on the ABI 7000 Sequence Detection System
and StepOnePlus™ Real-Time PCR System. Relative
mRNA expression was quantified using the comparative
Ct (ΔΔCt) method according to the ABI manual
(Applied Biosystems, Foster City, CA). Amplification of
glyceraldehyde-3-phosphated e h y d r o g e n a s e( G A P D H )
was used in each reaction as an internal reference gene.
Assays were performed in triplicate. TaqMan probes
were used for the human HNF4a (Hs00230853_m1),
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Figure 7 The ELK1 expression in HepG2 cells with HNF4a or
ELK1 knock-down. HepG2 cells were transfected with non-specific
siRNA control (siControl), HNF4a shRNA plasmid (siHNF4) or siELK1,
and then treated with or without cytokines. The expression of ELK1
was measured by real-time PCR. The results represent the relative
mRNA expression level normalized to GAPDH mRNA level. The
abundance of mRNA in the controls was set at 1. Data represent
mean ± SD of three different experiments. *p < 0.05 and **p < 0.01
indicate a significant difference compared to siControls.
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Page 10 of 14complement component 5 (C5, Hs00156197_m1), lipo-
polysaccharide binding protein (LBP, Hs00188074_m1),
serpin peptidase inhibitor member 3 (SERPINA3,
Hs00153674_m1), complement component 4A (C4A,
Hs00167147_m1), ELK1 (Hs00901847_m1), collagen,
type IV, alpha 1 (COL4A1, Hs01007469_m1), zinc finger
protein 175 (ZNF175, Hs00232535_m1), matrix metallo-
peptidase 15 (MMP15, Hs00233997_m1), SEC24 family,
member A (SEC24A, Hs00405228_m1) and GAPDH
(Hs99999905_m1) from the TaqMan
®Gene Expression
Assays (Applied Biosystems).
Microarray analysis
Affymetrix HG-U133A 2.0 GeneChips were used to
study the expression levels for HepG2 cell RNA. Sample
labeling, hybridization to microarrays, scanning and cal-
culation of normalized expression levels were carried
out at the Microarray Resource, Boston University
School of Medicine, Boston, MA. RNA samples (four
biological replicates for each of the four study groups:
control, HNF4a shRNA, cytokines, and HNF4a shRNA
with cytokine treatment) were analyzed. Microarray data
were quantified and normalized using Affymetrix Micro-
Array Suite (MAS) 5.0. Two-way ANOVA analysis was
then used to determine which probesets were differen-
tially expressed between the untreated control and trea-
ted groups. Only probesets exhibiting differential
expression with FDR < 0.01 were included in this study.
After the ANOVA analysis was performed, K-means
clustering was then used to cluster probesets that
siControl siHNF4 siELK1
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Figure 8 A decrease in ELK1 expression leads to elimination of the regulatory effect of HNF4a knock-down on a subset of genes.
HepG2 cells were treated with non-specific siRNA control (siControl), HNF4a shRNA plasmid (siHNF4), siELK1 or both siHNF4 and siELK1. The
expressions of COL4A1 (collagen, type IV, alpha 1), ZNF175 (zinc finger protein 175), MMP15 (matrix metallopeptidase 15) and SEC24A (SEC24
family, member A) genes were determined by real-time PCR. The abundance of mRNA in the siControl was set at 1. Data are presented as mean
± SD of three different experiments. *p < 0.05 and **p < 0.01 indicate a significant difference compared to siControl. #p < 0.01 indicates a
significant difference compared to siHNF4a.
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Page 11 of 14exhibit similar expression patterns within each category
of differential expression. In order to eliminate multiple
probesets, the raw data were clustered based on Unigene
identifiers (ids), which represent unique transcription
loci. Unigene ids associated with multiple probesets that
exhibit different patterns of expression were removed
from the dataset, ensuring unambiguous data that could
be easily used in subsequent enrichment analyses. This
approach ensures that, if anything, the results of subse-
quent analyses are conservative.
Gene ontology (GO) enrichment analysis
Before GO enrichment could be calculated, each GO
annotation was mapped to a corresponding Unigene id.
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Figure 9 The reduction of ELK1 level decreases the ability of HNF4a to interact with the promoters of a subset of genes. (A),H e p G 2
cells were transfected with siControl (siCtr) or siELK1. Protein interaction of HNF4a and ELK1 was determined by ChIP assay with either antibody
against HNF4a or goat normal IgG (IgG). Chromatin-immunoprecipitated DNA was analyzed by PCR with primers specific for the ELK1 binding
sites in the promoter regions of COL4A1, ZNF175, MMP15 and SEC24A genes. The result shown in (A) is a representative experiment, replicated
three times with similar results. (B), Histograms show densitometric analyses of relative binding abilities. Values represent mean ± SD of three
separate experiments. The relative quantitative analysis was carried out by comparison of siELK1 with siControl, and the siControl was set at 1.
*p < 0.05 and **p < 0.01 indicate a significant difference compared to siCtr. IP, immunoprecipitation.
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Page 12 of 14SwissProt ids associated with each Unigene id were
obtained and were used for this purpose. Where Swis-
sProt ids were not available, gene symbols were used to
associate GO annotations with Unigene ids. Each cluster
in all 4 categories was then tested for enrichment for
genes associated with inflammatory response GO data-
base (relative to the entire set of genes on the microarray)
using Fisher’s Exact test. In addition, to identify other
functionality, each cluster was tested for enrichment of
each of the top-level “biological process” annotations in
the GO database. As there are 26 top-level “biological
process”, a Bonferroni correction was applied for this
top-level analysis, resulting in a p-value cut-off of 0.002.
Promoter analysis
Weight matrices obtained from the JASPAR core data-
base [42] were used to identify potential transcription
factor binding sites in the up-stream of promoter
regions. One promoter with each Unigene id was
included in the analysis, so that genes with multiple
annotated promoters/TSS did not bias the analysis.
T h er e g i o n ,e x t e n d i n gf r o m- 1k bt o+ 0 . 5k br e l a t i v e
to the TSS, was extracted. Clover [34] was used with a
minimum log-ratio score cut-off of 8.0 to identify
potential binding sites in this region. Promoters were
classified based on whether they contain at least one
binding site, and enrichment in different expression
clusters relative to a background set of promoters
derived from all probesets present on the microarray.
The randomization feature of Clover was not used,
instead the exact number of promoters containing
binding sites in both the HNF4a-regulated set and the
background set were computed, and a p-value was cal-
culated using Fisher’s Exact test. Because there are
almost 140 transcription factors in the JASPAR data-
base, a Bonferroni correction was applied, resulting in
a p-value cut-off of 3.5 × 10
-4.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as described previously [21].
The purified chromatin was immunoprecipitated using
10 μg of anti-HNF-4a (sc-6556, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) or normal goat IgG (Santa Cruz).
After DNA purification, the presence of the ELK1 puta-
tive binding motif (CCGGAAG/A) DNA sequence was
assessed by PCR. The primers used were as follows: (1)
COL4A1 gene: 5’-GAGTTTAGCGCAGGATGAGG-3’
and 5’-GCTCTCCTGCTTGGGAGTAG-3’, and the PCR
product is 230 bp in length; (2) ZNF175: 5’-TAAAAGC
CCTTTGACGATGG-3’ and 5’-CTCTAGGCCACTT
CCGGTTT-3’, and the PCR product is 239 bp in length;
(3) MMP15: 5’-ATCCAGCTCGTTAAGCTTCG-3’ and
5’-TTAATCTCTCCGAGCCTCCA-3’ for amplifying a
207 bp DNA fragment. (4) SEC24A: 5’-GCACCAGGA
GCTGTCAGG-3’ and 5’-GGCAGCCAAACCTAGAG
AGA-3’, and the PCR product is 186 bp in length. The
PCR conditions were as following: 95°C for 10 min, fol-
lowed by 94°C for 45 s, 58°C for 60 s, and 72°C for 60 s
for a total of 31 cycles. In the ELK1 knock-down experi-
ments, the relative quantitative analysis in binding activ-
ity was performed, utilizing densitometry and statistical
analysis, by comparison of siELK1 with non-specific
siRNA control, and the control was set at 1.
Additional material
Additional file 1: Genes that respond to the treatment of HNF4a
knock-down and/or cytokines. This file includes four sub-tables
showing the genes with significantly altered expression and fold changes
in four categories (Category A to D).
Additional file 2: Construction of HNF4a siRNA-resistant mutant.
This file illustrates the generation and DNA sequencing of the HNF4a
siRNA-resistant construct.
Additional file 3: siRNA rescue assay. This file shows the
characterization of the HNF4a siRNA-resistant construct by Western blot,
and the rescue effect of this construct on HNF4a knock-down responsive
genes.
Additional file 4: ELK1 and HNF4a binding motifs in HNF4a-
regulated genes. This file shows the sequence and position of ELK1 and
HNF4a potential binding sites in the group of HNF4a-regulated genes.
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